Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | WRN | Q14191 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089097 | 0.81 | ALDH1A1 (0.32) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL15599422 | 0.76 | MGLL (0.40) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL4983632 | 0.74 | MGLL (0.37) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL19335970 | 0.73 | MGLL (0.35) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL21082757 | 0.72 | MGLL (0.34) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL25219511 | 0.65 | DNMT1 (0.41) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL25268047 | 0.65 | DNMT1 (0.41) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL31087099 | 0.65 | DNMT1 (0.41) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL12969435 | 0.63 | RXFP1 (0.33) | — | |
| SCHEMBL16786513 | 0.63 | ALDH1A1 (0.38) | ALDH1A1BLMGSK3AGSK3BHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822353-B2 | PEGylated aspartyl-tRNA synthetase polypeptides | ATYR PHARMA, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20150159148-A1 | PEGYLATED ASPARTYL-TRNA SYNTHETASE POLYPEPTIDES | ATYR PHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150159148-A1 | PEGYLATED ASPARTYL-TRNA SYNTHETASE POLYPEPTIDES | AARS1, GARS1, DARS1 | ALDH1A1 3820/4885HPGD 3332/4885CYP1A2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.